We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+30.98%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.69%
AUM
$283M
AUM Growth
+$43.4M
Cap. Flow
-$12.2M
Cap. Flow %
-4.31%
Top 10 Hldgs %
64.14%
Holding
48
New
7
Increased
14
Reduced
4
Closed
13
Avg Time Held
4 quarters
Top 10 Avg Time Held
2.7 quarters
Top 20 Avg Time Held
3.6 quarters

Top Buys

Rank Stock Value
1
CBAY icon
Cymabay Therapeutics
CBAY
+$4.5M
2
EGRX icon
Eagle Pharmaceuticals, Inc.
EGRX
+$4.23M
3
DCPH icon
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$3.98M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$3.06M
5
INSM icon
Insmed
INSM
+$2.29M

Top Sells

Rank Stock Value
1
BPMC icon
Blueprint Medicines
BPMC
+$7.75M
2
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
+$6.92M
3
ADMS
Adamas Pharmaceuticals
ADMS
+$5.07M
4
PRTA icon
Prothena Corp
PRTA
+$4.6M
5
HROW icon
Harrow
HROW
+$2.86M

Sector Composition

Rank Sector Weight
1 Healthcare 99.81%
2 Communication Services 0.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BPMC icon
1
DELISTED
Blueprint Medicines
BPMC
$51.2M 18.11%
735,000
-145,000
-16% -$7.75M
2015 Q3
8 quarters
AXGN icon
2
Axogen
AXGN
$2.18B
$38.1M 13.48%
1,970,000
– –
2015 Q1
10 quarters
KYNB icon
3
Kyntra Bio
KYNB
$24.8M
$19.4M 6.85%
14,400
– –
2014 Q4
11 quarters
IMMU
4
DELISTED
Immunomedics Inc
IMMU
$12.6M 4.44%
898,800
-1,200
-0.1% -$12K
2017 Q1
2 quarters
LOXO
5
DELISTED
Loxo Oncology, Inc
LOXO
$12M 4.23%
130,000
– –
2016 Q3
4 quarters
CDXS icon
6
Codexis
CDXS
$154M
$11.3M 4%
1,700,600
+230,600
+16% +$1.28M
2014 Q1
14 quarters
CORI
7
DELISTED
Corium International, Inc.
CORI
$10.2M 3.6%
920,000
+205,000
+29% +$1.81M
2015 Q4
7 quarters
MNTA
8
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$9.25M 3.27%
500,000
+50,000
+11% +$836K
2016 Q4
3 quarters
SGMO icon
9
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.7M 3.08%
580,000
– –
2016 Q4
3 quarters
AGIO icon
10
Agios Pharmaceuticals
AGIO
$1.84B
$8.68M 3.07%
130,000
– –
2016 Q1
6 quarters
CTMX icon
11
CytomX Therapeutics
CTMX
$527M
$8.18M 2.89%
450,000
-10,000
-2% -$156K
2016 Q2
5 quarters
SBBP
12
DELISTED
Strongbridge Biopharma plc.
SBBP
$8.14M 2.88%
1,180,000
– –
2016 Q4
3 quarters
EGRX icon
13
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$7.75M 2.74%
130,000
+70,000
+117% +$4.23M
2015 Q2
9 quarters
CMRX icon
14
DELISTED
Chimerix, Inc.
CMRX
$7.37M 2.6%
1,403,000
+123,000
+10% +$605K
2016 Q1
6 quarters
FOMX
15
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$6.34M 2.24%
1,142,000
+7,000
+0.6% +$36.2K
2015 Q2
9 quarters
XOMA icon
16
DELISTED
Xoma
XOMA
$6.29M 2.23%
320,200
+3,000
+0.9% +$33.5K
2017 Q1
2 quarters
TBPH icon
17
DELISTED
Theravance Biopharma
TBPH
$6.16M 2.18%
180,000
– –
2016 Q4
3 quarters
CBAY icon
18
DELISTED
Cymabay Therapeutics
CBAY
$5.36M 1.89%
+665,000
New +$4.5M
2017 Q3
0 quarters
BOLD icon
19
DELISTED
Audentes Therapeutics, Inc
BOLD
$5.04M 1.78%
180,000
+30,000
+20% +$651K
2017 Q2
1 quarter
SYBX icon
20
DELISTED
Synlogic
SYBX
$4.75M 1.68%
16,667
+5,733
+52% +$1.17M
2017 Q2
1 quarter
ENTA icon
21
Enanta Pharmaceuticals
ENTA
$358M
$4.68M 1.66%
100,000
– –
2016 Q4
3 quarters
DCPH icon
22
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$4.12M 1.46%
+217,000
New +$3.98M
2017 Q3
0 quarters
ARDX icon
23
Ardelyx
ARDX
$834M
$3.92M 1.39%
700,000
+153,500
+28% +$809K
2017 Q2
1 quarter
XLRN
24
DELISTED
Acceleron Pharma
XLRN
$3.79M 1.34%
101,500
+1,500
+2% +$52.1K
2017 Q2
1 quarter
INSM icon
25
Insmed
INSM
$21.5B
$3.75M 1.32%
+120,000
New +$2.29M
2017 Q3
0 quarters
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2017 Portfolio in Review

As of Q3 2017, Opaleye Management held 48 positions worth $283M, up 18% from $239M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Opaleye Management withdrew a net $12.2M in Q3 2017, closing 13 positions and reducing 4 holdings. Its most notable exit was Novelion Therapeutics Inc. Common Shares, an estimated $6.92M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Communication Services.

Against the trend, Opaleye Management opened a new position in Cymabay Therapeutics worth $5.36M.

  • Opaleye Management's largest Q3 2017 buy was Cymabay Therapeutics: 665,000 shares worth $5.36M.
  • Opaleye Management added most to Eagle Pharmaceuticals, Inc. in Q3 2017, an estimated $4.23M increase.
  • Opaleye Management's biggest Q3 2017 reduction was Blueprint Medicines, cutting an estimated $7.75M.
  • Opaleye Management fully exited Novelion Therapeutics Inc. Common Shares in Q3 2017, selling an estimated $6.92M.
  • Opaleye Management's ten largest holdings make up 64% of its $283M portfolio in Q3 2017.
  • Opaleye Management opened 7 new positions and closed 13 in Q3 2017.
  • Opaleye Management's portfolio value rose 18% quarter-over-quarter to $283M.

Based on Opaleye Management's 13F filing for Q3 2017, filed 14 Nov 2017.